Lexaria Bioscience Corp.
LEXX
$4.93
-$0.94-15.94%
NASDAQ
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -37.32% | 9.09% | 40.83% | 28.85% | -39.65% |
| Total Depreciation and Amortization | 0.75% | 9.92% | -15.38% | -24.74% | 313.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.58% | -23.34% | -72.35% | -31.79% | 209.26% |
| Change in Net Operating Assets | 129.04% | -266.10% | 251.37% | 5.87% | -133.06% |
| Cash from Operations | 24.44% | -119.89% | 62.76% | 26.27% | -139.27% |
| Capital Expenditure | 100.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -106.87% | -156.86% | 96.77% | -713.92% | 30.47% |
| Cash from Investing | 49.72% | -956.86% | 96.77% | -713.92% | 30.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -12.38% | -- | -100.00% | 14,336.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -12.38% | -- | -100.00% | 14,336.75% |
| Foreign Exchange rate Adjustments | -56.31% | 461.40% | -153.27% | -71.24% | 139.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -295.19% | -65.84% | 188.87% | -48.60% | -16.65% |